Ironwood Pharmaceuticals
NasdaqGS:IRWD Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
WA
Consensus Narrative from 5 Analysts
Focusing On LINZESS And Apraglutide Will Improve Future Prospects
Key Takeaways Strong LINZESS demand and apraglutide's market potential could drive future revenue, contingent on stable pricing and regulatory success. Reduced R&D spending and strategic focus on high-potential assets may enhance financial stability and boost future earnings.
View narrativeUS$12.17
FV
83.6% undervalued intrinsic discount9.99%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
21 days ago author updated this narrative